Last reviewed · How we verify
L-arginine and liposomal vitamin C
L-arginine and liposomal vitamin C is a Nutritional supplement combination Small molecule drug developed by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. It is currently in Phase 3 development for COVID-19 (phase 3 trial context), Vascular dysfunction and endothelial dysfunction.
L-arginine enhances nitric oxide production to improve vascular function, while liposomal vitamin C provides antioxidant support and may enhance immune function.
L-arginine enhances nitric oxide production to improve vascular function, while liposomal vitamin C provides antioxidant support and may enhance immune function. Used for COVID-19 (phase 3 trial context), Vascular dysfunction and endothelial dysfunction.
At a glance
| Generic name | L-arginine and liposomal vitamin C |
|---|---|
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
| Drug class | Nutritional supplement combination |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Immunology |
| Phase | Phase 3 |
Mechanism of action
L-arginine is a semi-essential amino acid that serves as a substrate for nitric oxide synthase, promoting vasodilation and improving endothelial function. Liposomal vitamin C (ascorbic acid in liposomal formulation) enhances bioavailability and provides antioxidant effects, potentially reducing oxidative stress and supporting immune responses. Together, these agents may work synergistically to improve vascular health and reduce inflammatory markers.
Approved indications
- COVID-19 (phase 3 trial context)
- Vascular dysfunction and endothelial dysfunction
Common side effects
- Gastrointestinal disturbance
- Nausea
- Diarrhea
- Headache
Key clinical trials
- Effects of L-arginine and Liposomial Vitamin C on Severe Copd Patients Undergoing Pulmonary Rehabilitation. (NA)
- Effects of L-ARGinine and Liposomal Vitamin C Supplementation On Physical Performance (NA)
- Evaluation of the Effect of Liposomal L-Arg and Vit C Integration on Mitochondrial Function in Patients With Heart Failure (PHASE3)
- Evaluation of the Effects of Treatment With Bioarginin C in Adult Subjects Belonging to the Post-Covid Day Hospital (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-arginine and liposomal vitamin C CI brief — competitive landscape report
- L-arginine and liposomal vitamin C updates RSS · CI watch RSS
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico portfolio CI
Frequently asked questions about L-arginine and liposomal vitamin C
What is L-arginine and liposomal vitamin C?
How does L-arginine and liposomal vitamin C work?
What is L-arginine and liposomal vitamin C used for?
Who makes L-arginine and liposomal vitamin C?
What drug class is L-arginine and liposomal vitamin C in?
What development phase is L-arginine and liposomal vitamin C in?
What are the side effects of L-arginine and liposomal vitamin C?
Related
- Drug class: All Nutritional supplement combination drugs
- Manufacturer: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico — full pipeline
- Therapeutic area: All drugs in Cardiovascular / Immunology
- Indication: Drugs for COVID-19 (phase 3 trial context)
- Indication: Drugs for Vascular dysfunction and endothelial dysfunction